Long-term Survival in B-precursor Acute Leukemia Treated With Blinatumomab Assessed

Share this content:
About one-third of adult patients with B-precursor acute lymphoblastic leukemia had a survival of at least 30 months when administered blinatumomab.
About one-third of adult patients with B-precursor acute lymphoblastic leukemia had a survival of at least 30 months when administered blinatumomab.

Approximately one-third of adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) had a survival of at least 30 months in a study where they were administered blinatumomab, according to an article published online ahead of print in Blood.1  

Investigators conducted a long-term follow-up analysis on overall survival and relapse-free survival in a phase 2 study of 36 adults with relapsed/refractory ALL who were treated with the bispecific T-cell engager (BiTE®) antibody construct blinatumomab.

Primary analysis revealed that 69% of patients achieved complete remission with full (CR) or partial (CRh) recovery of peripheral blood counts within the first 2 cycles.

Minimal residual disease (MRD) response (<10-4 blasts) was achieved in 25 (69%) of patients, with 22 achieving CR/CRh.

Median overall survival was 13.0 months. A total of 10 (28%) of patients were long-term survivors, with an overall survival ≥30 months. Long-term survival was associated with MRD, T-cell expansion, and B cell depletion.

RELATED: Inotuzumab Ozogamicin Granted Breakthrough Therapy Designation for Acute Leukemia

Median relapse-free survival was 8.8 months, with a median follow-up of 28.9 months.

In regard to safety, three long-term survivors experienced neurologic events or cytokine release syndrome that resulted in temporary treatment discontinuation.   

Reference

  1. Zugmaier G, Gӧkbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in adult patients with relapsed/refractory B-precursors acute lymphoblastic leukemia who achieved minimal residual disease response following treatment with Anti-CD19 BiTE® antibody construct blinatumomab [published onhile ahead of print October 19, 2015]. Blood. doi: 10.1182/blood-2015-06-649111.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs